New hope for rare stomach cancer patients as targeted drug trial opens
NCT ID NCT07434843
Summary
This study is testing whether the drug pemigatinib can help control advanced gastrointestinal stromal tumors (GIST) that have a specific genetic deficiency called SDH. About 24 adults with this rare tumor type who have already tried other treatments will take the drug daily in 21-day cycles. Researchers will measure how well the tumors shrink and monitor side effects to see if this targeted approach works for this specific cancer type.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTROINTESTINAL STROMAL TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-••••
Locations
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02115, United States
Conditions
Explore the condition pages connected to this study.